Skip to Main Content


Skip Nav Destination

Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Cancer Res (2021) 81 (13_Supplement): CT238.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal